In this article, we report a 40-year-old male patient with ankylosing spondylitis who developed Philadelphia chromosome-positive acute lymphoid leukemia after treatment with tumor necrosis factor-alpha inhibitors.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:The efficacy and safety of anti-tumor necrosis factor-alpha drugs have been shown in active ankylosing spondylitis cases that are resistant to traditional disease-modifying antirheumatic drugs.
📊
Key Findings & Data:However, it is well known that these drugs may cause some complications as reactivation of tuberculosis and various hematologic malignancies.
💡
Conclusion & Impact:In this article, we report a 40-year-old male patient with ankylosing spondylitis who developed Philadelphia chromosome-positive acute lymphoid leukemia after treatment with tumor necrosis factor-alpha inhibitors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
The efficacy and safety of anti-tumor necrosis factor-alpha drugs have been shown in active ankylosing spondylitis cases that are resistant to traditional disease-modifying antirheumatic drugs. However, it is well known that these drugs may cause some complications as reactivation of tuberculosis and various hematologic malignancies. In this article, we report a 40-year-old male patient with ankylosing spondylitis who developed Philadelphia chromosome-positive acute lymphoid leukemia after treatment with tumor necrosis factor-alpha inhibitors.
🔖
Cite This Article
ÖZDEMİRKIRAN, F. G., PAYZIN, B. K., ÇOBAN, E., BAYRAM, K. B., KÜÇÜKZEYBEK, B. B. (2015). Acute Lymphoid Leukemia After Anti-TNF-alpha Treatment: A Case Report and Review of the Literature. art, Cilt: 30 - Sayı: 4, 349–352. https://ajindex.com/articles/195494
Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52
Reed MR, Taylor AL. Tumour necrosis factor inhibitors in ankylosing spondylitis. Intern Med J 2008;38:781-9
Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51
Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, et al. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol 2014;66:1282-90
Bakland G, Nossent H. Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford) 2003;42:900-1
Alert F. Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). FDA Alert [Access: August 04, 2009]
Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007;82:1022-4
Bachmeyer C, Thiolière B, Khosrotehrani K, Cattan E. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 2007;56:169-70
Saba NS, Kosseifi SG, Charaf EA, Hammad AN. Adalimumab-induced acute myelogenic leukemia. South Med J 2008;101:1261-2
Kemta Lekpa F, Zahra K, Pautas C, Maury S, Chevalier X, Claudepierre P. Acute myeloid leukemia after infliximab: a case report. Clin Exp Rheumatol 2009;27:999-1000
Knudson RM, Tefferi A, Pittelkow MR, Davis MD. Development of myelo